Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
Jackson, David J. et al. European Respiratory Journal 64.1 (2024): 2301521. Abstract Background Pivotal phase 3 trials and real-world studies have demonstrated benralizumab’s overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed…